Biogen | BIIB - Ordinary Share Capital


Biogen reported $146.7M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
ALKERMES USD 166.46M 855K Mar/2026
Amgen USD 540M 1000K Mar/2026
Bayer EUR 982.42M 0 Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Teva Pharmaceutical Industries USD 1.16B 16.72M Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026